文献速递中枢神经肿瘤放疗

新诊断胶质母细胞瘤患者在接受5毫米边界的5次立体定向放射外科联合替莫唑胺的1/2期试验中的进展模式

Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant Temozolomide.
PubMed 文献 · Pract Radiat Oncol · 2023-02-02

30例新诊断胶质母细胞瘤患者接受5次立体定向放射外科(总边界5毫米,剂量25-40 Gy)联合替莫唑胺。27例进展患者中,野内进展17例(63%),边缘进展3例(11%),远处进展7例(26%)。仅1例(4%)可能从常规20毫米边界获得剂量学获益;放射性坏死与野内肿瘤控制相关。

要点

  • 5毫米边界下,野内进展17例(63%),边缘进展3例(11%),远处进展7例(26%)。
  • 边缘进展的3例中,仅1例(4%)可能从常规20毫米边界获得剂量学获益。
  • 发生放射性坏死的患者野内进展比例更低(1/7,14% vs 16/20,80%;P=0.003)。

核心结论

  • 在接受5毫米临床靶区边界治疗的新诊断胶质母细胞瘤患者中,3例(11%)出现5至20毫米的边缘进展;仅1例(4%)可能从常规20毫米边界获得剂量学获益。
  • 放射性坏死与野内肿瘤控制相关。

研究设计与样本

  • 1/2期试验,纳入30例新诊断胶质母细胞瘤成人患者,接受5次立体定向放射外科治疗,总治疗边界5毫米,剂量递增至25至40 Gy。
  • 进展按几何模式分类:野内(复发肿瘤位于5毫米边界内或与之连续)、边缘(5至20毫米之间)、远处(完全大于20毫米)。
  • 计算肿瘤复发部位每日最小等效2 Gy剂量(EQD2);若每日最小EQD2覆盖达48 Gy10,则判为剂量学野内。

主要发现

  • 2010年至2016年,27例患者出现进展;野内进展17例(63%),边缘进展3例(11%),远处进展7例(26%)。
  • 3例边缘进展患者中,复发肿瘤的最小EQD2分别为48 Gy10、56 Gy10(两者均判为剂量学野内)和7 Gy10(即剂量学野外)。
  • 野内进展的中位总生存为12.1个月(95%CI 8.9-17.6),边缘进展为15.1个月(95%CI 10.1至未达到),远处进展为21.4个月(95%CI 11.2-33.5)。
  • 发生放射性坏死的患者野内进展比例更低(1/7,14%),而无放射性坏死者为16/20(80%)(P=0.003);坏死患者中位总生存27.2个月(95%CI 11.2-48.3),无坏死患者为11.7个月(95%CI 8.9-17.6)(P=0.077)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with newly diagnosed glioblastoma (GBM), tumor margins of at least 20 mm are the standard of care. We sought to determine the pattern of tumor progression in patients treated with 5-fraction stereotactic radiosurgery with 5-mm margins. METHODS AND MATERIALS: Thirty adult patients with newly diagnosed GBM were treated with 5-fraction stereotactic radiosurgery in escalated doses from 25 to 40 Gy with a 5-mm total treatment margin. Progression was scored as "in-field" if the recurrent tumor was within or contiguous with the 5-mm margin, "marginal" if between 5 and 20 mm, and "distant" if entirely occurring greater than 20 mm. As geometric patterns of progression do not reflect the biologic dose received, we calculated the minimum equi-effective dose in 2 Gy (EQD2) per day at the site of tumor recurrence. Progression was "dosimetrically in-field" if covered by a minimum EQD2 per day of 48 Gy10. RESULTS: From 2010 to 2016, 27 patients had progressed. Progression was in-field in 17 (63%), marginal in 3 (11%), and distant in 7 (26%) patients. In the 3 patients with marginal progression, the minimum EQD2 to recurrent tumor were 48 Gy10, 56 Gy10 (both considered dosimetrically in-field), and 7 Gy10 (ie, dosimetrically out-of-field). Median overall survival was 12.1 months for in-field (95% confidence interval [CI], 8.9-17.6), 15.1 months (95% CI, 10.1 to not achieved) for marginal, and 21.4 months (95% CI, 11.2-33.5) for distant progression. Patients with radiation necrosis were less likely to have in-field progression (1 of 7; 14%) compared with those without radiation necrosis (16 of 20; 80%; P = .003); those with necrosis had a median overall survival of 27.2 months (95% CI, 11.2-48.3) compared with 11.7 months (95% CI, 8.9-17.6) for patients with no necrosis (P = .077). CONCLUSIONS: In patients with newly diagnosed GBM treated with a 5-mm clinical target volume margin, 3 patients (11%) had marginal progression within 5 to 20 mm; only 1 patient (4%) may have dosimetrically benefitted from conventional 20-mm margins. Radiation necrosis was associated with in-field tumor control.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mendoza MG, Azoulay M, Chang SD, et al. Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant Temozolomide. Pract Radiat Oncol. 2023. PMID: 36736621. doi:10.1016/j.prro.2023.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。